Despite a sluggish economy, intense competition, pricing pressures, litigation, and the significant impact of generic contraceptives, growth in this market is expected to accelerate at a better than average pace throughout the forecast period, as the contraceptives segment, in particular, benefits from highly positive insurance reimbursement (as a result of the 2010 Affordable Care Act) and increasing consumer affordability. The contraceptives market is also expected to flourish due to the introduction of several safer, more tolerable, lower-dosage, yet highly effective contraceptive drugs, and strong advertising/marketing efforts by major pharmaceutical firms. Additionally, the market is benefiting from increased consumer preference and usage of novel contraceptive devices and implants, which provide a convenient, long-term alternative for preventing pregnancy, especially in women who cannot tolerate, or fail to adhere to required dosing schedules of oral drug therapies.
The U.S. market for reproductive management products will also benefit from continued strong demand for easier-to-use, highly effective fertility drugs, as well as the introduction of new technologies, which are expected to enhance assisted reproductive technology and further improve pregnancy rates and decrease potential side effects.
Overall, the U.S. market for reproductive management products will continue to benefit from the stability and growth of the aging female population in the U.S., which continues to postpone or refrain from childbearing and demand access to highly effective contraceptives and fertility drugs.
This dynamic report from Medtech Insight includes analyses of products, markets, competitors, emerging technology and opportunities. Covered products include oral, transdermal, injectable and emergency contraceptives; contraceptive devices, including intrauterine devices (IUDs), vaginal rings, and subdermal contraceptive implants; and leading fertility drug therapies and devices, among other products.
EXECUTIVE SUMMARY i. Contraceptive Drugs and Devices ii. Fertility Treatment iii. Combined Market Forecast iv. Methodology Exhibit ES-1: Reproductive Management Products Market, Combined Market Forecast, 2012-2017 Exhibit ES-2: Reproductive Management Products, Market Forecast, by Product Segment, 2012-2017 Exhibit ES-3: 2012, Reproductive Management Products Market, Share of Sales, by Product Segment Exhibit ES-4: 2017, Reproductive Management Products Market, Share of Sales, by Product Segment 1. CONTRACEPTIVE DRUGS AND DEVICES 1.1 Contraceptive Drugs 1.1.1 Actavis 1.1.2 Bayer 1.1.3 Janssen Pharmaceuticals/Johnson & Johnson 1.1.4 Merck & Company 1.1.5 Pfizer 1.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries 1.1.7 Market Forecast 1.1.8 Competitive Analysis 1.2 Contraceptive Devices 1.2.1 Actavis 1.2.2 Bayer 1.2.3 The Female Health Company 1.2.4 FemCap 1.2.5 Mayer Laboratories 1.2.6 Merck & Company 1.2.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries 1.2.8 Market Forecast 1.2.9 Competitive Analysis 1.3 Nonsurgical Sterilization 1.3.1 Bayer 1.3.2 Hologic Exhibit 1-1: 2013, Selected Contraceptive Drugs Exhibit 1-2: 2013, Selected Contraceptive Drugs Under Development Exhibit 1-3: The Average Reduction in Menstrual Bleeding Using Natazia Over a 90-day Assessment Phase in 2 Studies Exhibit 1-4: Contraceptive Drugs, Market Forecast, 2012-2017 Exhibit 1-5: 2012, Contraceptive Drugs Market, Share by Supplier Exhibit 1-6: 2013, Selected Leading Contraceptive Devices Exhibit 1-7: 2013, Selected Contraceptive Devices Under Development Exhibit 1-8: The Mirena Intrauterine Device Exhibit 1-9: The FemCap Cervical Cap Exhibit 1-10: The NuvaRing Vaginal Contraceptive Ring Exhibit 1-11: Efficacy of the NuvaRing Compared to Other Contraceptive Methods Exhibit 1-12: The Implanon Subdermal Contraceptive Implant Exhibit 1-13: Efficacy of Implanon Compared to Other Contraceptive Methods Exhibit 1-14: The ParaGard Intrauterine Device Exhibit 1-15: Contraceptive Devices, Market Forecast, 2012-2017 Exhibit 1-16: 2012, Contraceptive Devices Market, Share by Supplier Exhibit 1-17: The Essure Three-Step Sterilization Procedure 2. FERTILITY DRUGS AND DEVICES 2.1 Selected Fertility Drug Treatments 2.1.1 Actavis 2.1.2 EMD Serono/Merck KGaA 2.1.3 Ferring Pharmaceuticals 2.1.4 Merck & Company 2.1.5 OvaScience 2.1.6 Teva Pharmaceuticals/Teva Pharmaceutical Industries 2.1.7 Market Forecast 2.1.8 Competitive Analysis 2.2 Embryo Transfer Catheters 2.2.1 CooperSurgical/The Cooper Companies 2.2.2 Irvine Scientific/JX Group 2.3 Assisted Natural Conception 2.3.1 Cambridge Temperature Concepts Exhibit 2-1: 2013, Selected Fertility Drug Therapies Exhibit 2-2: 2013, Selected Immunoassays and Fertility Treatments Under Development Exhibit 2-3: Efficacy of Crinone in Maintaining Full-Term Pregnancies Following In Vitro Fertilization Embryo Transfer Exhibit 2-4: Efficacy of Crinone in Maintaining Full-Term Pregnancies versus No Supplemental Progesterone for Luteal Phase Support Exhibit 2-5: The Gonal-f RFF Pen Exhibit 2-6: Fertility Drugs, Market Forecast, 2012-2017 Exhibit 2-7: 2012, Fertility Drugs Market, Share by Supplier Exhibit 2-8: The R.G. Edwards Embryo Transfer Catheters Exhibit 2-9: The Classic Ultrasoft Embryo Transfer Catheters and Stylets Exhibit 2-10: The DuoFertility Assisted Natural Conception System 3. COMPANY PROFILES 3.1 Actavis, Inc. 3.2 Bayer AG 3.3 Ferring Pharmaceuticals A/S 3.4 Johnson & Johnson 3.5 Merck & Company, Inc. 3.6 Merck KGaA 3.7 Teva Pharmaceuticals/Teva Pharmaceutical Industries LTD APPENDIX: COMPANY LISTING